Compugen is standing firm on its belief that TIGIT will ultimately succeed with Fc reduced/silent constructs episode artwork

EPISODE · Nov 8, 2025 · 11 MIN

Compugen is standing firm on its belief that TIGIT will ultimately succeed with Fc reduced/silent constructs

from BiotechTV - News · host BiotechTV

The company's new CEO Eran Ophir discusses the computational work that when into Compugen's understanding of TIGIT biology, and he walks us through their partnership with AstraZeneca. Plus, recent ESMO data for PVRIG and a trial in progress for IL18BP.

The company's new CEO Eran Ophir discusses the computational work that when into Compugen's understanding of TIGIT biology, and he walks us through their partnership with AstraZeneca. Plus, recent ESMO data for PVRIG and a trial in progress for IL18BP.

NOW PLAYING

Compugen is standing firm on its belief that TIGIT will ultimately succeed with Fc reduced/silent constructs

0:00 11:53

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of BiotechTV - News?

This episode is 11 minutes long.

When was this BiotechTV - News episode published?

This episode was published on November 8, 2025.

What is this episode about?

The company's new CEO Eran Ophir discusses the computational work that when into Compugen's understanding of TIGIT biology, and he walks us through their partnership with AstraZeneca. Plus, recent ESMO data for PVRIG and a trial in progress for...

Can I download this BiotechTV - News episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!